Saturday 17 October 2026
Export MLSS’s income statement to Excel — free account
Milestone Scientific, Inc.
MLSS Healthcare Medical Instruments & Supplies
Milestone Scientific, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, up 3.99% from fiscal 2024. In the quarter to June 2026, revenue grew 22.3%, EPS grew 50.0%, free cash flow grew 66.7% and total debt fell 43.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.33
0.00
0.00%
Follow MLSS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.15 | 2.47 | 2.77 | 3.16 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
452.88 | (98.00) | 284.13 | (50.93) | |
P/B ratio |
14.53 | 7.88 | 10.79 | 8.59 | |
Price to Tangible BV |
15.10 | 8.11 | 11.09 | 8.70 | |
EV/Sales |
4.09 | 2.44 | 2.73 | 2.99 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(8.69) | (7.50) | (13.33) | (43.90) | |
EV/FCF |
(8.27) | (6.99) | (11.94) | (32.98) | |
Quick Ratio |
0.41 | 0.44 | 0.36 | 0.71 | |
Current Ratio |
1.61 | 1.81 | 1.51 | 1.85 | |
Net Debt/EBITDA |
0.47 | 0.28 | 0.48 | 1.57 | |
Debt/Assets |
9.83% | 10.60% | 10.30% | 5.75% | |
Debt/Equity |
0.33 | 0.29 | 0.36 | 0.14 | |
Asset Turnover |
0.91 | 1.02 | 1.04 | 1.15 | |
Operating CF/Net income |
(0.07) | 0.21 | (0.10) | 0.55 | |
Capex/Depreciation |
(0.16) | (0.06) | (0.03) | (0.09) | |
Interest Coverage |
(58.18) | — | — | — | |
Research and Development Expense of Revenue |
0.69% | 0.60% | 0.00% | 0.23% | |
Selling, General and Administrative Expense of Revenue |
116.05% | 123.90% | 109.75% | 103.68% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
15.38% | 25.97% | 14.44% | 14.05% | |
Graham Net Nets |
0.06 | 0.11 | 0.07 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.67%) | (23.70%) | (18.62%) | (13.75%) | |
Free Cash Flow Yield |
(11.92%) | (14.12%) | (8.25%) | (2.87%) | |
Revenue per Share |
0.03 | 0.03 | 0.03 | 0.03 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Cash per Share |
0.02 | 0.01 | 0.01 | 0.02 | |
Shareholders Equity per Share |
0.03 | 0.03 | 0.03 | 0.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.03 | 0.03 | 0.03 | 0.04 | |
Free Cash Flow |
0.08 | (0.23) | 0.09 | (0.59) | |
Working Capital |
3.08 | 3.35 | 2.50 | 3.72 | |
Capital Expenditures |
(0.01) | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
2.17 | 2.48 | 1.67 | 3.24 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.64 | 0.59 | 0.55 | 0.87 | |
Average Payables |
2.46 | 2.15 | 2.97 | 2.41 | |
Average Inventory |
3.92 | 3.75 | 3.83 | 3.49 | |
Average Assets |
9.83 | 8.80 | 8.53 | 8.20 | |
Average Common Equity |
4.89 | 4.32 | 3.37 | 3.41 |
Columns are period end dates